AstraZeneca Pharma (India) Ltd. has recently announced securing approval from the Central Drugs Standard Control Organisation (CDSCO) to import and distribute Durvalumab (Imfinzi) in two dosage strengths: 120 mg/2.4 mL and 500 mg/10 mL, marking an important milestone, allowing the company to introduce new cancer treatment options for Indian patients, particularly those suffering from non-small …


